RESUMO
BACKGROUND: Capillary hemangiomas of the skin and soft tissue are a common entity, while capillary hemangiomas of the central nervous system are an extremely rare pathology. There are less than 20 published cases of intradural lesions involving the cauda equina. CASE PRESENTATION: Herein, we describe a young patient with a capillary hemangioma of the cauda equina that underwent successful surgical resection. CONCLUSION: Natural history and post-operative follow-up for patients with spinal intradural capillary hemangioma are uncertain. This is the sole case to have not recurred at 12 months which underwent gross total resection and had a high proliferative index.
Assuntos
Cauda Equina/patologia , Hemangioma Capilar/patologia , Recidiva Local de Neoplasia/patologia , Neoplasias do Sistema Nervoso Periférico/patologia , Adulto , Diagnóstico Diferencial , Hemangioma Capilar/diagnóstico , Humanos , Imageamento por Ressonância Magnética , Masculino , Recidiva Local de Neoplasia/diagnóstico , Neoplasias do Sistema Nervoso Periférico/diagnósticoRESUMO
Improving outcomes for diffuse glioma patients requires methods that can accurately and sensitively monitor tumour activity and treatment response. Extracellular vesicles (EV) are membranous nanoparticles that can traverse the blood-brain-barrier, carrying oncogenic molecules into the circulation. Measuring clinically relevant glioma biomarkers cargoed in circulating EVs could revolutionise how glioma patients are managed. Despite their suitability for biomarker discovery, the co-isolation of highly abundant complex blood proteins has hindered comprehensive proteomic studies of circulating-EVs. Plasma-EVs isolated from pre-operative glioma grade II-IV patients (n = 41) and controls (n = 11) were sequenced by Sequential window acquisition of all theoretical fragment ion spectra mass spectrometry (SWATH-MS) and data extraction was performed by aligning against a custom 8662-protein library. Overall, 4054 proteins were measured in plasma-EVs. Differentially expressed proteins and putative circulating-EV markers were identified (adj. p-value < 0.05), including those reported in previous in-vitro and ex-vivo glioma-EV studies. Principal component analysis showed that plasma-EV protein profiles clustered according to glioma histological-subtype and grade, and plasma-EVs resampled from patients with recurrent tumour progression grouped with more aggressive glioma samples. The extensive plasma-EV proteome profiles achieved here highlight the potential for SWATH-MS to define circulating-EV biomarkers for objective blood-based measurements of glioma activity that could serve as ideal surrogate endpoints to assess tumour progression and allow more dynamic, patient-centred treatment protocols.
Assuntos
Neoplasias Encefálicas/sangue , Vesículas Extracelulares/metabolismo , Glioma/sangue , Proteômica/métodos , Adulto , Idoso , Biomarcadores Tumorais/sangue , Neoplasias Encefálicas/classificação , Neoplasias Encefálicas/patologia , Estudos de Casos e Controles , Micropartículas Derivadas de Células/metabolismo , Micropartículas Derivadas de Células/ultraestrutura , Estudos de Coortes , Vesículas Extracelulares/ultraestrutura , Feminino , Glioma/classificação , Glioma/patologia , Humanos , Biópsia Líquida/métodos , Masculino , Pessoa de Meia-Idade , Espectrometria de Massas em Tandem/métodos , Fluxo de TrabalhoRESUMO
Extracellular vesicles (EVs) play key roles in glioblastoma (GBM; astrocytoma grade IV) biology and are novel sources of biomarkers. EVs released from GBM tumors can cross the blood-brain-barrier into the periphery carrying GBM molecules, including small non-coding RNA (sncRNA). Biomarkers cargoed in circulating EVs have shown great promise for assessing the molecular state of brain tumors in situ. Neurosurgical aspirate fluids captured during tumor resections are a rich source of GBM-EVs isolated directly from tumor microenvironments. Using density gradient ultracentrifugation, EVs were purified from cavitron ultrasonic surgical aspirate (CUSA) washings from GBM (n = 12) and astrocytoma II-III (GII-III, n = 5) surgeries. The sncRNA contents of surgically captured EVs were profiled using the Illumina® NextSeqTM 500 NGS System. Differential expression analysis identified 27 miRNA and 10 piRNA species in GBM relative to GII-III CUSA-EVs. Resolved CUSA-EV sncRNAs could discriminate serum-EV sncRNA profiles from GBM and GII-III patients and healthy controls and 14 miRNAs (including miR-486-3p and miR-106b-3p) and cancer-associated piRNAs (piR_016658, _016659, _020829 and _204090) were also significantly expressed in serum-EVs. Circulating EV markers that correlate with histological, neuroradiographic and clinical parameters will provide objective measures of tumor activity and improve the accuracy of GBM tumor surveillance.
Assuntos
Astrocitoma/química , Líquidos Corporais/química , Química Encefálica , Neoplasias Encefálicas/química , Micropartículas Derivadas de Células/química , Glioblastoma/química , Biópsia Líquida , MicroRNAs/análise , RNA Neoplásico/análise , Astrocitoma/sangue , Astrocitoma/diagnóstico , Astrocitoma/cirurgia , Biomarcadores Tumorais/análise , Biomarcadores Tumorais/sangue , Neoplasias Encefálicas/sangue , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/cirurgia , Centrifugação com Gradiente de Concentração , Diagnóstico Diferencial , Glioblastoma/sangue , Glioblastoma/diagnóstico , Glioblastoma/cirurgia , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , MicroRNAs/sangue , Gradação de Tumores , Procedimentos Neurocirúrgicos , Especificidade de Órgãos , RNA Neoplásico/sangue , RNA Interferente Pequeno/análise , RNA Interferente Pequeno/sangue , RNA-Seq , Microambiente TumoralRESUMO
Glioblastoma, WHO-grade IV glioma, carries a dismal prognosis owing to its infiltrative growth and limited treatment options. Glioblastoma-derived extracellular vesicles (EVs; 30-1000 nm membranous particles) influence the microenvironment to mediate tumor aggressiveness and carry oncogenic cargo across the blood-brain barrier into the circulation. As such, EVs are biomarker reservoirs with enormous potential for assessing glioblastoma tumors in situ. Neurosurgical aspirates are rich sources of EVs, isolated directly from glioma microenvironments. EV proteomes enriched from glioblastoma (n = 15) and glioma grade II-III (n = 7) aspirates are compared and 298 differentially-abundant proteins (p-value < 0.00496) are identified using quantitative LC-MS/MS. Along with previously reported glioblastoma-associated biomarkers, levels of all eight subunits of the key molecular chaperone, T-complex protein 1 Ring complex (TRiC), are higher in glioblastoma-EVs, including CCT2, CCT3, CCT5, CCT6A, CCT7, and TCP1 (p < 0.00496). Analogous increases in TRiC transcript levels and DNA copy numbers are detected in silico; CCT6A has the greatest induction of expression and amplification in glioblastoma and shows a negative association with survival (p = 0.006). CCT6A is co-localized with EGFR at 7p11.2, with a strong tendency for co-amplification (p < 0.001). Immunohistochemistry corroborates the CCT6A proteomics measurements and indicated a potential link between EGFR and CCT6A tissue expression. Putative EV-biomarkers described here should be further assessed in peripheral blood.
Assuntos
Biomarcadores Tumorais/metabolismo , Neoplasias Encefálicas/metabolismo , Neoplasias Encefálicas/patologia , Chaperonina com TCP-1/metabolismo , Vesículas Extracelulares/metabolismo , Glioblastoma/metabolismo , Glioblastoma/patologia , Chaperonina com TCP-1/química , Cromatografia Líquida , Glioma/metabolismo , Glioma/patologia , Humanos , Prognóstico , Proteômica , Espectrometria de Massas em TandemRESUMO
Leptomeningitis is a rare central nervous system manifestation of rheumatoid arthritis, generally in patients with established chronic rheumatoid disease. We report a 41-year-old man without previous rheumatoid arthritis or psychiatric disorder who presented with an acute neuropsychiatric disturbance and polyarthralgia. His MR scan of brain showed asymmetric bifrontal leptomeningitis, confirmed on (18F)-fluoro-D-glucose-positron emission tomography. Other investigations showed highly positive serum and cerebrospinal fluid anti-cyclic citrullinated peptide. A leptomeningeal biopsy showed necrotising leptomeningeal inflammation with ill-defined granulomas and lymphoplasmacytic infiltrate without organisms. Prolonged high-dose corticosteroids and then rituximab resulted in recovery. Chronic leptomeningitis can present with an acute neuropsychiatric disorder. We highlight that early rheumatoid disease can, rarely, cause a chronic leptomeningitis, reversible with immunotherapy.
Assuntos
Artrite Reumatoide/complicações , Meningite/etiologia , Transtornos Mentais/etiologia , Adulto , Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Humanos , Masculino , Meningite/tratamento farmacológico , Rituximab/uso terapêuticoRESUMO
Central nervous system (CNS) tumours were one of the first cancer types to adopt and integrate molecular profiling into routine clinical diagnosis in 2016. The vast majority of these biomarkers, used to discriminate between tumour types, also offered prognostic information. With the advent of The Cancer Genome Atlas (TCGA) and other large genomic datasets, further prognostic sub-stratification was possible within tumour types, leading to increased precision in CNS tumour grading. This review outlines the evolution of the molecular landscape of adult CNS tumours, through the prism of World Health Organization (WHO) Classifications. We begin our journey in the pre-molecular era, where high-grade gliomas were divided into 'primary' and 'secondary' glioblastomas. Molecular alterations explaining these clinicopathological observations were the first branching points of glioma diagnostics, with the discovery of IDH1/2 mutations and 1p/19q codeletion. Subsequently, the rigorous characterisation of paediatric gliomas led to the unearthing of histone H3 alterations as a key event in gliomagenesis, which also had implications for young adult patients. Simultaneously, studies investigating prognostic biomarkers within tumour types were undertaken. Certain genomic phenotypes were found to portend unfavourable outcomes, for example, MYCN amplification in spinal ependymoma. The arrival of methylation profiling, having revolutionised the diagnosis of CNS tumours, now promises to bring increased prognostic accuracy, as has been shown in meningiomas. While MGMT promoter hypermethylation has remained a reliable biomarker of response to cytotoxic chemotherapy, targeted therapy in CNS tumours has unfortunately not had the success of other cancers. Therefore, predictive biomarkers have lagged behind the identification of prognostic biomarkers in CNS tumours. Emerging research from new clinical trials is cause for guarded optimism and may shift our conceptualisation of predictive biomarker testing in CNS tumours.
Assuntos
Neoplasias Encefálicas , Neoplasias do Sistema Nervoso Central , Glioma , Adulto Jovem , Humanos , Criança , Prognóstico , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/terapia , Neoplasias do Sistema Nervoso Central/diagnóstico , Neoplasias do Sistema Nervoso Central/genética , Glioma/diagnóstico , Glioma/genética , Biomarcadores , Mutação , Isocitrato Desidrogenase/genética , Biomarcadores Tumorais/genéticaRESUMO
BACKGROUND: The current methods to predict recurrence and aggressive behaviour of meningiomas rely mainly on histological grading, histological subtype, proliferative index, as well as brain invasion. In many instances, histological grade alone fails to predict recurrence in the grade I and grade II meningiomas. Deletions of 1p and 14q have previously been reported to correlate with poor prognosis in terms of either recurrence or higher histological grades. The Her2neu (ErbB2) amplification has been shown to be a useful predictor of aggressive behaviour in breast and ovarian tumours, but its significance in meningioma is so far uncertain. METHOD: In order to determine the cytogenetic differences between 22 recurrent and 25 non-recurrent meningiomas of all grades, we used fluorescent in situ hybridization (FISH) DNA probes for 1p36, 14q11.2 and 17q11.2-12 (Her2neu) on formalin fixed paraffin embedded (FFPE) tissue from the Brain Tumour Tissue Bank (BTTB), London Health Science Center (LHSC). RESULTS: We showed a positive association for meningioma recurrence correlated with 1p36 deletion plus or minus 14q 11.2 deletions in all grades of meningiomas. The Her2neu amplification was strongly associated with 1p/14q co-deletion in cases of recurrent meningiomas, especially the higher grade tumours. CONCLUSION: These cytogenetic markers can be applied in addition to histological grading for predicting the risk of recurrence and biological behaviour.
Assuntos
Deleção Cromossômica , Cromossomos Humanos Par 14/genética , Neoplasias Meníngeas/genética , Meningioma/genética , Recidiva Local de Neoplasia/genética , Receptor ErbB-2/genética , Cromossomos Humanos Par 1/genética , Citogenética , Feminino , Estudos de Associação Genética , Humanos , Hibridização in Situ Fluorescente , Estudos Longitudinais , MasculinoRESUMO
Chronic traumatic encephalopathy (CTE) is a neuropathological diagnosis defined by a unique pattern of hyperphosphorylated tau (p-tau) accumulation that begins in neocortical regions of the brain. It is associated with a range of neuropsychological symptoms, but a definitive diagnosis can only be made by postmortem brain examination. In 2018, we instituted CTE screening for all autopsy brains as part of our routine departmental protocol by performing p-tau immunohistochemistry on a restricted set of 3 neocortical blocks (frontal, temporal, and parietal). This strategy allowed us to identify 4 cases of low-stage CTE from 180 consecutive autopsies. Two of the 4 cases had a documented history of brain injury; for the remaining 2 cases, there was a long history of treatment-resistant tonic/clonic epilepsy suggesting that undocumented brain injuries may have occurred. Our experience indicates that 3-block CTE screening is useful in identifying CTE in routine practice. The results of this study further support the association between prior head injuries and CTE and demonstrate that, albeit uncommon, CTE does occur in the general population. Our findings suggest that p-tau screening should be routinely pursued in brain autopsy, particularly where there is a documented or likely history of traumatic brain injury.
Assuntos
Lesões Encefálicas Traumáticas , Encefalopatia Traumática Crônica , Encéfalo/patologia , Lesões Encefálicas Traumáticas/complicações , Lesões Encefálicas Traumáticas/patologia , Encefalopatia Traumática Crônica/patologia , Humanos , Neuropatologia , Proteínas tau/metabolismoRESUMO
Background: Histone mutant gliomas (HMG) with histone H3 K27 and G34 mutations are recognized as biologically discrete entities with distinct anatomical locations, younger age at presentation (in comparison to the most common high-grade gliomas, IDH wildtype glioblastoma), and poor prognosis. There is a paucity of data regarding the management of adult HMG patients and no consensus on management. This study aims to identify current patterns of Australian and US neuro-oncology clinical practice for this entity. Methods: Following institutional approvals, patterns of care questionnaire designed to capture relevant clinical variables was circulated through the Cooperative Trials Group for Neuro-Oncology (COGNO) in Australia and the Caris Precision Oncology Alliance in the United States (US). Results: Between 4/2021 and 10/2021, 43 responses were collected. 33% (n = 14) of responders tested all patients for HMGs routinely; 40.92% (n = 18) tested in select patients 26% (n = 11) did not test for HMGs. The common indications for testing selected patients were midline anatomic location (n = 18) and age (n = 11) (<50 years). 23 used molecular sequencing, 22 used IHC at their centers. Nine participants stated knowledge of histone H3 mutations did not affect their management of these gliomas, 11 said it affected their management at the time of recurrence, 23 stated it affected the management of midline K27M patients, 11 participants stated it affected the management of K27M mutant gliomas in other locations, and 3 felt it affected the management of G34R/V mutant gliomas. Conclusion: Here we present a description of how the discovery of a new molecular subtype of primary glial tumors, histone mutated gliomas in adults, is being introduced into clinical practice.
RESUMO
PURPOSE: The aim of this study was to investigate the relationship between tumor budding and other pathology features and overall survival after resection of clinicopathological stage III colon cancer. METHODS: The number of buds and other histopathological features were assessed in 477 patients who were operated on between 1971 and 2001, with follow-up to December 2006. Overall survival was analyzed using the Kaplan-Meier method and Cox regression. RESULTS: The number of buds was dichotomized as low (0 to 8) vs high (>or=9). High budding was more common in men, in high-grade tumors, in the presence of venous invasion, and where the tumor had involved a free serosal surface, but budding was not associated with 8 other clinical and pathological features. The 5-year survival rate for patients with 0 to 8 buds was 51.0% (95% confidence interval, 44.9-55.1), whereas that for patients with 9 or more buds was 33.9% (95% confidence interval, 25.2-42.8). This association, however, disappeared after adjustment for other variables independently associated with survival (hazard ratio, 1.2; 95% confidence interval, 0.94-1.54; P = .139). CONCLUSION: In stage III colon cancer, tumor budding did not provide additional independent prognostic information beyond that given by routine pathology reporting.
Assuntos
Transformação Celular Neoplásica/patologia , Neoplasias do Colo/patologia , Neoplasias do Colo/cirurgia , Adulto , Idoso , Distribuição de Qui-Quadrado , Feminino , Humanos , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/patologia , Estadiamento de Neoplasias , Valor Preditivo dos Testes , Prognóstico , Modelos de Riscos Proporcionais , Sistema de Registros , Estudos Retrospectivos , Taxa de SobrevidaRESUMO
BACKGROUND: Mixed pituitary adenoma-gangliocytomas are rare tumors with a broad morphologic spectrum. Smear cytology is a useful tool for recognizing these tumors in an intraoperative setting. CASES: The patients were 45 and 30 years old, and both presented with headache. Intraoperative smears in both cases showed a tumor composed of adenomatous and neuronal elements, in varying proportions. The first case had sheets of monotonous neuroendocrine-type cells with occasional interspersed ganglion cells. The second case, however, had a prominent fibrillary background and was predominantly neurocytic, with a mixture of large ganglion-like cells, intermediate cells, and only rare adenomatous cells. CONCLUSION: The diagnostic features of mixed pituitary adenoma-gangliocytomas can be recognized on intraoperative smear preparations. Smear preparations are often more useful than frozen sections because freezing artifacts may mask one of the two components of the tumor. The proportion of adenomatous and neuronal elements can vary widely from case to case. Careful search for a neuronal component should be made, especially if there is a clinical history of a pituitary adenoma showing incomplete response to hormonal therapy.
Assuntos
Ganglioneuroma/patologia , Neoplasias Hipofisárias/patologia , Adulto , Feminino , Ganglioneuroma/cirurgia , Humanos , Pessoa de Meia-Idade , Neoplasias Hipofisárias/cirurgiaRESUMO
Formalin-fixed, paraffin-embedded tissue (FFPE) still plays an important role in biobanking, since it is comparatively easy to obtain and store in comparison to fresh frozen tissue. They are stored as paraffin or FFPE blocks. Unstained slides derived from FFPE blocks may be used for hematoxylin and eosin histology, special stains, immunohistochemistry, and chromogenic or fluorescent in situ hybridization. In addition, tissue scraped off FFPE slides or from scrolls of FFPE tissue may be used for molecular or proteomic analyses. Hematoxylin and eosin staining of FFPE sections reviewed by a pathologist are highly valuable to ensure the presence of adequate lesional cells for molecular and other analyses. Therefore, proper microtomy technique is essential in the preparation of formalin-fixed, paraffin-embedded tissue for biobanking purposes. Here we describe the process of cutting paraffin embedded sections using a rotary microtome. We also highlight the possible pitfalls that may arise and discuss how to avoid them.
Assuntos
Bancos de Espécimes Biológicos , Microtomia , Inclusão em Parafina/métodos , Proteômica , Fixadores/química , Humanos , Hibridização in Situ Fluorescente , Fixação de TecidosRESUMO
In the original publication of this article [1] the term 'National Rugby League (NRL)' was used to refer to professional rugby league competition sport in Australia. The term should have read 'professional rugby league' to include the various professional competition nomenclatures over the last fifty years, including but not limited to NRL. In this correction article, the incorrect and correct information are published.